Long Acting HIV Prevention Methods

Available via

WEBINAR

FREE

for Members

Long Acting HIV Prevention Methods

Friday, September 22, 2017

The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York

The development of antiretroviral drugs for HIV has dramatically reduced disease burden for millions of people with access to adequate treatment and prevention programs. However, UNAIDS reports that 25 million people in Sub-Saharan Africa are still living with HIV, accounting for more than two-thirds of the infected population worldwide, and that women (aged 15-24) in this region are disproportionately impacted. Importantly, the number of young women at the cusp of this age range is currently very high, placing us at an important juncture. Without adequate intervention and a reduction in the rate of new infections, the most likely outcome is a resurgence of the HIV epidemic.

The scientific community must develop new and effective prevention strategies to reduce HIV transmission in order to prevent this devastating outcome. Taking into consideration economic, social, and cultural barriers to current HIV prevention strategies, approaches such as long-acting therapies are a promising path forward, however key questions remain before this approach can be put to use in community settings. This conference will address current scientific barriers to development of long-acting prevention methods for HIV.

Registration for this conference is FREE.

Registration

Member
$0
Nonmember
$0
Nonmember Student, Undergrad, Grad, Fellow
$0
Member Student, Post-Doc, Fellow
$0
Member
$0
Nonmember
$0
Nonmember Student, Undergrad, Grad, Fellow
$0
Member Student, Post-Doc, Fellow
$0

**will not be participating in the webinar or eBriefing

Organizers

Long Acting HIV Prevention Methods
Charles Gombar, PhD, The Bill & Melinda Gates Foundation
Long Acting HIV Prevention Methods
Thomas Hope, PhD, Feinberg School of Medicine, Northwestern University
Long Acting HIV Prevention Methods
John Mascola, MD, National Institute of Allergy and Infectious Diseases
Long Acting HIV Prevention Methods
Michel C. Nussenzweig, MD, PhD, The Rockefeller University
Long Acting HIV Prevention Methods
John Pottage, MD, ViiV Healthcare
Long Acting HIV Prevention Methods
Nina Russell, MD, The Bill & Melinda Gates Foundation
Long Acting HIV Prevention Methods
Sonya Dougal, PhD, The New York Academy of Sciences

Friday

September 22, 2017

Session 1: The Challenge of Effective Anti-HIV Biomedical Prevention

9:00 AM

Opening Remarks

Speakers

Sonya Dougal, PhD
The New York Academy of Sciences
Charles Gombar, PhD
The Bill & Melinda Gates Foundation
9:15 AM

Control of the HIV Epidemic: The Challenges and the Potential for Failure

Speaker

Emilio Emini, PhD
The Bill & Melinda Gates Foundation
9:35 AM

Learnings from the Use of Currently Available Biomedical Interventions

Speaker

Mitchell Warren
AIDS Vaccine Advocacy Coalition
9:55 AM

Q&A/Discussion

Speakers

Moderator: Charles Gombar, PhD
The Bill & Melinda Gates Foundation
Emilio Emini, PhD
The Bill & Melinda Gates Foundation
Mitchell Warren
AIDS Vaccine Advocacy Coalition
10:15 AM

Networking Coffee Break

Session 2: Novel Small Molecule Prevention Interventions

10:45 AM

Cabotegravir Long-Acting (CAB LA) Intramuscular Injectable Suspension: A New Candidate for HIV Prevention

Speaker

Alex Rinehart, PhD
ViiV Healthcare
11:05 AM

Promising Single Agent ARVs for Prevention

Speaker

Trevor Hawkins, MD
Gilead
11:25 AM

Dapivirine Ring: Clinical Data and Delivery Plans

Speaker

Zeda Rosenberg, ScD
International Partnership for Microbicides
11:45 AM

Q&A/Discussion

Speakers

Moderator: Magdalena Sobieszczyk, MD, MPH
Columbia University
Trevor Hawkins, MD
Gilead
Alex Rinehart, PhD
ViiV Healthcare
Zeda Rosenberg, ScD
International Partnership for Microbicides
12:15 PM

Lunch

Session 3: Drug Delivery Technologies

1:15 PM

Challenges of Developing Sustained Release Formulations of Antiretrovirals for PrEP

Speaker

Tom Hope, PhD
Feinberg School of Medicine, Northwestern University
1:35 PM

Self-Assembled Hydrogels as Long-Acting Injectables

Speaker

Nitin Joshi, PhD
Massachusetts Institute of Technology
1:55 PM

Q&A/Discussion

Speakers

Moderator: John Mascola, MD
National Institute of Allergy and Infectious Diseases
Tom Hope, PhD
Feinberg School of Medicine, Northwestern University
Nitin Joshi, PhD
Massachusetts Institute of Technology
2:25 PM

Networking Coffee Break

Session 4: Novel Biological Interventions

2:55 PM

Clinical Development HIV-1 bNAbs for Prevention

Speaker

John Mascola, MD **
National Institute of Allergy and Infectious Diseases (**will not be participating in the webinar or eBriefing)
3:15 PM

Broadly Neutralizing Antibodies for HIV Prevention

Speaker

Marina Caskey, MD
The Rockefeller University
3:35 PM

Development of PGT121 and PGDM1400

Speaker

Dan Barouch, MD **
Beth Israel Deaconess Medical Center (**will not be participating in the webinar or eBriefing)
3:55 PM

Optimizing bnAbs for Manufacturability and Stability

Speaker

Bruce Kerwin, PhD
Just Biotherapeutics
4:15 PM

Q&A/Discussion

Speakers

Moderator: Pervin Anklesaria, PhD
The Bill & Melinda Gates Foundation
Dan Barouch, MD
Beth Israel Deaconess Medical Center
Marina Caskey, MD
The Rockefeller University
Bruce Kerwin, PhD
Just Biotherapeutics
John Mascola, MD
National Institute of Allergy and Infectious Diseases
4:45 PM

Closing Remarks

Speaker

Pervin Anklesaria, PhD
The Bill & Melinda Gates Foundation
4:50 PM

Networking Reception